中华眼科杂志最新文献

{"title":"[Clinical applications and future perspectives of ultra-widefield swept-source optical coherence tomography angiography in ophthalmology].","authors":"X Z Wang, W Han","doi":"10.3760/cma.j.cn112142-20251223-00547","DOIUrl":"https://doi.org/10.3760/cma.j.cn112142-20251223-00547","url":null,"abstract":"<p><p>Optical coherence tomography angiography (OCTA) is a noninvasive, depth-resolved imaging modality that visualizes ocular microvascular networks based on blood flow-related motion contrast, without exogenous contrast agents. Owing to its ability to provide high-resolution, layer-specific vascular information, OCTA has become an indispensable tool in both clinical practice and ophthalmic research. The advent of swept-source OCTA (SS-OCTA), characterized by longer imaging wavelengths and faster scanning speeds, has enabled wider fields of view and deeper tissue penetration. These technical advances have driven the development of ultra-widefield SS-OCTA (UWF SS-OCTA), substantially enhancing visualization of the peripheral retina and anterior segment vasculature. This review outlines the fundamental principles and technological evolution of OCTA, with particular emphasis on recent progress in the clinical applications of UWF SS-OCTA across a spectrum of ophthalmic diseases. In addition, we discuss emerging opportunities for integrating artificial intelligence-based algorithms with UWF SS-OCTA to facilitate quantitative vascular analysis, disease assessment, and precision-oriented diagnosis and management.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"62 10","pages":"885-892"},"PeriodicalIF":0.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149149545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effects of asiatic acid on angiogenesis and Slit-Robo signaling in retinal microvascular endothelial cells induced by high glucose].","authors":"M Y Fang, F Q Zhang, Y Qi, M L Qin, J X Song, J F Liu, K Li, L Li, G Y Zheng","doi":"10.3760/cma.j.cn112142-20260316-00105","DOIUrl":"https://doi.org/10.3760/cma.j.cn112142-20260316-00105","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To explore the effects and mechanism of asiatic acid (AA) on high glucose (HG)-induced angiogenesis of human retinal microvascular endothelial cells (hRMECs). &lt;b&gt;Methods:&lt;/b&gt; In this experimental study, the MTT assay was used to screen the optimal concentration of AA. The HG-induced hRMEC injury models were established and divided into the control group, HG group, Mannitol group, HG+AA group, HG+AA+740Y-P group, HG+LY294002 group and HG+dimethyl sulfoxide group. Cell viability, migration and tube formation were detected by the MTT assay, scratch test and Matrigel assay, respectively. Real-time PCR and ELISA were used to detect the relative mRNA expression of Slit guidance ligand 2 (&lt;i&gt;Slit2&lt;/i&gt;) and roundabout guidance receptor 1 (&lt;i&gt;Robo1&lt;/i&gt;), as well as Slit2 secretion. Western blot was used to detect the protein expression of phosphatidylinositol 3-kinase p85 subunit (PI3K p85), phosphorylated PI3K p85 (p-PI3K p85), protein kinase B (AKT), phosphorylated AKT (p-AKT), Slit2 and Robo1. &lt;b&gt;Results:&lt;/b&gt; The treatment with 10 μmol/L AA did not affect the viability of normal hRMECs (0.803±0.05) (&lt;i&gt;P&lt;/i&gt;=0.662), but significantly inhibited cell viability under HG conditions (1.049±0.12) (&lt;i&gt;P&lt;/i&gt;&lt;0.001). Compared with the control group, the HG group showed significant increases in cell viability (1.609±0.14), migration rate (70.90%±5.39%), tube number (61.89±2.17), number of master junctions (96.22±3.86), total tube length [(28 043.78±1 472.75) μm], mRNA and protein expression of &lt;i&gt;Slit2&lt;/i&gt; (4.07±0.31 and 4.76±0.72), Slit2 secretion [(5.889±0.746) ng/ml], mRNA and protein expression of &lt;i&gt;Robo1&lt;/i&gt; (4.46±0.17 and 6.00±0.35), as well as protein expression of p-PI3K p85 (6.61±0.46) and p-AKT (6.02±0.68) (all &lt;i&gt;P&lt;/i&gt;&lt;0.001). Compared with the HG+dimethyl sulfoxide group, the HG+AA group exhibited significant decreases in cell viability (1.052±0.14) (&lt;i&gt;P&lt;/i&gt;=0.002), migration rate (30.70%±3.97%), tube number (42.22±4.17) (&lt;i&gt;P&lt;/i&gt;=0.004), number of master junctions (69.89±1.34) (&lt;i&gt;P&lt;/i&gt;&lt;0.001), total tube length [(19 853.11±1 141.85) μm] (&lt;i&gt;P&lt;/i&gt;&lt;0.001), mRNA and protein expression of &lt;i&gt;Slit2&lt;/i&gt; (2.02±0.04 and 2.12±0.17), Slit2 secretion [(2.991±0.479) ng/ml] (&lt;i&gt;P&lt;/i&gt;&lt;0.001), mRNA and protein expression of &lt;i&gt;Robo1&lt;/i&gt; (1.99±0.13 and 2.86±0.28) (&lt;i&gt;P&lt;/i&gt;&lt;0.001), and protein expression of p-PI3K p85 (1.84±0.22) and p-AKT (2.30±0.15) (&lt;i&gt;P&lt;/i&gt;&lt;0.001). Compared with the HG+AA group, the HG+AA+740Y-P group showed significant increases in cell viability (1.517±0.14) (&lt;i&gt;P&lt;/i&gt;=0.012), migration rate (68.12%±3.70%) (&lt;i&gt;P&lt;/i&gt;&lt;0.001), tube number (56.44±4.07) (&lt;i&gt;P&lt;/i&gt;=0.009), number of master junctions (93.67±3.85) (&lt;i&gt;P&lt;/i&gt;&lt;0.001), total tube length [(27 751.22±1 148.29) μm] (&lt;i&gt;P&lt;/i&gt;&lt;0.001), mRNA and protein expression of &lt;i&gt;Slit2&lt;/i&gt; (3.47±0.15 and 4.05±0.25) (&lt;i&gt;P&lt;/i&gt;&lt;0.001), Slit2 secretion [(4.763±0.565) ng/ml] (&lt;i&gt;P&lt;/i&gt;=0.023), mRNA and protein expression of &lt;i&gt;Robo1&lt;/i&gt; (3.95±0.11 and 5.39±0.46) (&lt;i&gt;P&lt;/i&gt;&lt;0.001), and pr","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"62 10","pages":"844-854"},"PeriodicalIF":0.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149149761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Adjustment of contact lens parameters to improve insufficient sagittal height for treatment of corneal injury: a case report].","authors":"L Liu, Z Li, J L Peng","doi":"10.3760/cma.j.cn112142-20251118-00487","DOIUrl":"https://doi.org/10.3760/cma.j.cn112142-20251118-00487","url":null,"abstract":"<p><p>A 14-year-old female patient presented to the Department of Ophthalmology, the First Affiliated Hospital of Xiangnan University with a 3-year history of blurred vision while wearing single-vision spectacles for bilateral myopia. The patient demonstrated satisfactory corrected visual acuity, rapid myopia progression, no manifest strabismus, and well-preserved fusional function and stereopsis; therefore, orthokeratology was administered. Grade 2 central corneal staining developed at one month. Lens parameters were adjusted to optimize the fitting: the power of the alignment curve was reduced by 0.25 D, the toricity was increased, the sagittal depth of the reverse curve was raised by 20 μm, and the peripheral curve was upgraded by one step. Following these adjustments, the corneal staining resolved completely, and the uncorrected visual acuity improved to 1.0. After eight months of lens wear, the axial length regressed by 0.18 to 0.27 mm.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"62 10","pages":"865-868"},"PeriodicalIF":0.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese expert consensus on the management of corneal and ocular surface adverse events related to antibody-drug conjugates (2026)].","authors":"","doi":"10.3760/cma.j.cn112142-20260107-00010","DOIUrl":"10.3760/cma.j.cn112142-20260107-00010","url":null,"abstract":"<p><p>Antibody-drug conjugates (ADCs), as a novel class of targeted anticancer therapies, have demonstrated significantly enhanced efficacy. However, the associated ocular adverse events have emerged as a critical issue impacting patients' quality of life and treatment compliance. ADC-induced ocular adverse events primarily affect corneal and ocular surface tissues. With the recent approval of multiple ADC agents in China and the extensive ongoing clinical trials, standardized guidance for managing corneal and ocular surface adverse events is urgently needed. The Dry Eye Research Group of Ophthalmology Branch of Chinese National Health Association and the Dry Eye Rehabilitation Specialty of Vision Rehabilitation Committee of Chinese Rehabilitation Medicine Association, together with experts from relevant fields, have developed consensus recommendations based on integrated international research and Chinese clinical practice, using the standardized consensus development methods. These recommendations address eight clinical questions concerning corneal and ocular surface adverse events associated with ADCs, aiming to provide evidence-based guidance for the prevention, diagnosis, and management of ADC-related corneal and ocular surface adverse events. Through multidisciplinary collaboration, this consensus seeks to enhance therapeutic benefits of ADC treatment and maximize patients' visual health and quality of life.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"62 10","pages":"784-791"},"PeriodicalIF":0.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149148542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Pythium keratitis: a case report].","authors":"M Xuan, B Y Yang, L Y Liang","doi":"10.3760/cma.j.cn112142-20251022-00438","DOIUrl":"10.3760/cma.j.cn112142-20251022-00438","url":null,"abstract":"<p><p>A 31-year-old female presented with a 3-week history of right eye redness, ocular pain, photophobia and decreased vision after tap water exposure. Slit-lamp examination revealed corneal lesions with pseudopodia and hill-shaped hypopyon. <i>In vivo</i> confocal microscopy (IVCM) detected filament-like structures in the corneal stroma. The patient was initially suspected of having fungal keratitis, but the condition deteriorated despite standardized antifungal treatment. Repeated corneal scraping culture and targeted DNA sequencing confirmed the infection of <i>Pythium insidiosum</i>. After switching to linezolid-based antibacterial therapy, corneal perforation still occurred, and total keratoplasty with a scleral ring was performed. The infection relapsed at 2 weeks postoperatively and was finally controlled by multiple intracameral and intrastromal injections of linezolid. A secondary penetrating keratoplasty was subsequently performed. No recurrence was observed during the 11-month follow-up; the corneal graft remained transparent, and the best corrected visual acuity improved to 0.6. <i>Pythium</i> species are oomycetes instead of true fungi, which are intrinsically resistant to conventional antifungal agents but susceptible to specific antibacterial drugs such as linezolid. For clinically suspected Pythium keratitis unresponsive to antifungal treatment, early targeted DNA sequencing is essential for rapid pathogen identification. Timely administration of sensitive antibacterial agents and individualized surgical intervention are critical to control infection and optimize visual prognosis.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"62 10","pages":"855-860"},"PeriodicalIF":0.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149149527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Emphasizing ocular surface status management throughout the course of glaucoma diagnosis and treatment].","authors":"X H Sun, J Y Chen","doi":"10.3760/cma.j.cn112142-20260712-00298","DOIUrl":"10.3760/cma.j.cn112142-20260712-00298","url":null,"abstract":"<p><p>Glaucoma is a major cause of irreversible blindness worldwide, and patients often require long-term or even lifelong topical intraocular pressure-lowering therapy. With prolonged treatment, the combined effects of active drug ingredients, preservative exposure, age-related ocular surface changes, and surgery-related factors make ocular surface disease a common yet easily overlooked comorbidity in patients with glaucoma. Ocular surface abnormalities may cause ocular discomfort and fluctuating vision, reduce medication adherence, interfere with intraocular pressure measurement and disease assessment, increase the difficulty of perioperative management, and affect long-term treatment efficacy and quality of life. This article emphasizes the need to change the clinical tendency of focusing on intraocular pressure while neglecting the ocular surface, and to incorporate ocular surface assessment and intervention into the entire course of glaucoma diagnosis and management. While protecting the optic nerve, clinicians should also maintain the homeostasis of the ocular surface microenvironment, thereby promoting long-term individualized management of glaucoma.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"62 9","pages":"671-675"},"PeriodicalIF":0.0,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese expert consensus on the diagnosis and treatment of pediatric vernal keratoconjunctivitis (2026)].","authors":"","doi":"10.3760/cma.j.cn112142-20260504-00183","DOIUrl":"10.3760/cma.j.cn112142-20260504-00183","url":null,"abstract":"<p><p>Vernal keratoconjunctivitis (VKC) is a chronic, seasonal, recurrent, bilateral allergic inflammatory disease that predominantly affects children, severely impacting patients' quality of life. The early diagnosis rate of VKC in Chinese children is relatively low, treatment regimens vary, and clinical efficacy is difficult to guarantee. To guide the related clinical practice, the Cornea Group of Ophthalmology Branch of Chinese Medical Association, together with the Chinese Association for Pediatric Ophthalmology and Strabismus, developed expert consensus recommendations for the diagnosis and treatment of pediatric VKC. These recommendations were formulated by integrating evidence-based medical research results from both domestic and international sources and expert clinical experience, and using standardized guideline and consensus development methods.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"62 9","pages":"676-684"},"PeriodicalIF":0.0,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Tafluprost/timolol fixed-dose combination versus tafluprost monotherapy for open-angle glaucoma and ocular hypertension: a multicenter, randomized, double-blind, parallel-group trial].","authors":"K D Wang, P Zhao, L L Wu, T H Zhang, H Z Zhou, Y L Wang, J B Wang, M Ke, X L Xing, J Yang, H Dai, D B Wang, X C Duan, Q Zhao, Y H Wang, M K Lin, L S Tang, M W Zhao, A W Fang, K Yao, Y J Zheng, J L Hao, L Xu, J Zhou, C Liu, X H Sun","doi":"10.3760/cma.j.cn112142-20251230-00559","DOIUrl":"10.3760/cma.j.cn112142-20251230-00559","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the efficacy and safety of a preservative-free tafluprost/timolol maleate fixed-dose combination compared with preservative-free tafluprost monotherapy in Chinese patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). <b>Methods:</b> This was a multicenter, randomized, double-blind, parallel-controlled clinical trial conducted across 25 centers, including the Eye & ENT Hospital of Fudan University, from January 2019 to November 2022. Patients diagnosed with OAG or OHT who required enhanced intraocular pressure (IOP) reduction after a 4-week washout period were enrolled. Participants were randomized 1∶1 to receive either tafluprost/timolol or tafluprost once daily for 3 months. The primary endpoint was the change from baseline in mean diurnal IOP (the average of measurements at 8:00, 10:00, and 16:00) at Month 3. Secondary endpoints included IOP changes at individual time points and the proportion of responders achieving predefined IOP reduction thresholds. Safety was assessed via the incidence of adverse events (AEs). Analysis of covariance (ANCOVA) using the Markov Chain Monte Carlo (MCMC) method was employed for the primary endpoint; superiority was established if the upper limit of the 95% confidence interval (<i>CI</i>) was<0 mmHg (1 mmHg=0.133 kPa). Continuous variables in secondary endpoints were compared using ANCOVA, and responder rates were analyzed using Fisher's exact test. <b>Results:</b> A total of 219 patients were enrolled (tafluprost/timolol group: <i>n</i>=110; tafluprost group: n=109). The primary efficacy analysis set included 215 patients (tafluprost/timolol: <i>n</i>=107; tafluprost: <i>n</i>=108). Baseline characteristics were well-balanced between the two groups. The majority of patients were male [127 (59.1%)] with a mean age of (44.80±15.71) years at screening. At Month 3, the mean diurnal IOP reduction from baseline was (6.56±3.44) mmHg in the tafluprost/timolol group and (5.36±2.94) mmHg in the tafluprost group. After adjusting for baseline IOP, the between-group difference was -1.312 mmHg (95%<i>CI</i>: -2.010 to -0.696); as the upper limit was<0 mmHg, tafluprost/timolol demonstrated superior IOP-lowering efficacy to tafluprost. Responder rates for IOP reductions of≥15%,≥25%, and≥30% were significantly higher in the tafluprost/timolol group (<i>P</i>=0.016, 0.028, and 0.032, respectively). The incidence of ocular AEs was 20.0% (22/110) in the tafluprost/timolol group and 26.6% (29/109) in the tafluprost group. The most common AE was conjunctival hyperemia, occurring in 2.7% (3/110) and 8.3% (9/109) of the groups, respectively. <b>Conclusion:</b> Compared with preservative-free tafluprost monotherapy, the tafluprost/timolol combination provides significantly greater IOP reduction in patients with OAG and OHT, while maintaining a favorable safety profile.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"62 9","pages":"691-699"},"PeriodicalIF":0.0,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical outcomes of a monocular bi-aspheric ablation profile for the correction of refractive errors associated with presbyopia].","authors":"S Y Zhu, M J Ma, X Wei, S Chen, X L Sheng","doi":"10.3760/cma.j.cn112142-20260508-00188","DOIUrl":"https://doi.org/10.3760/cma.j.cn112142-20260508-00188","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To explore the safety, efficacy, predictability, binocular visual balance, and postoperative visual quality of a monocular bi-aspheric ablation profile combined with laser corneal refractive surgery in patients with refractive errors associated with presbyopia, and to provide clinical evidence for individualized surgical correction of presbyopia. &lt;b&gt;Methods:&lt;/b&gt; This retrospective case series study included 64 patients (128 eyes) with refractive errors and presbyopia treated at Gansu Aier Eye Hospital from April 2022 to April 2026, comprising 25 males and 39 females with a mean age of (46.66±4.87) years. The dominant eye was designated for distance vision and treated with small-incision lenticule extraction (SMILE) or femtosecond laser-assisted laser in situ keratomileusis (FS-LASIK) according to the corneal characteristics and refractive status; the non-dominant eye was designated for near vision and treated with a monocular bi-aspheric ablation profile combined with FS-LASIK, in which a certain degree of residual myopia and negative spherical aberration were intentionally induced to increase depth of focus and enhance near vision. Postoperative follow-ups were conducted at 1 day, 1 month, 3 months, and 6 months. Binocular uncorrected distance visual acuity(BUDVA), binocular uncorrected near visual acuity (BUNVA), refractive outcomes, higher-order aberrations, and subjective visual quality were evaluated. &lt;b&gt;Results:&lt;/b&gt; Subgroup analysis based on dominant-eye surgical procedure showed no significant differences in postoperative binocular distance or near visual acuity between the SMILE and LASIK groups. Pooled analysis showed that BUDVA remained stable throughout follow-up and was comparable to the preoperative level, while BUNVA was significantly improved postoperatively. At 1 month postoperatively, 94.2%(49/52) of patients achieved binocular uncorrected distance visual acuity of 20/25 or better, and 80.7%(42/52) achieved 20/20 or better; meanwhile, 94.2%(49/52) achieved BUNVA of 0.8 or better, and 80.7% (42/52)achieved 1.0 or better. The median efficacy index was 1.11 (interquartile range, 1.0 to 1.2). Postoperatively, uncorrected distance visual acuity was significantly better in the dominant eye than in the non-dominant eye (&lt;i&gt;P&lt;/i&gt;&lt;0.001), whereas uncorrected near visual acuity was significantly better in the non-dominant eye than in the dominant eye (&lt;i&gt;P&lt;/i&gt;=0.010), indicating successful establishment of the intended monocular bi-aspheric visual profile. At 6 months, actual spherical equivalent correlated strongly with the predicted values in both dominant and non-dominant eyes (&lt;i&gt;R&lt;/i&gt;²=0.924 and 0.922, respectively; all &lt;i&gt;P&lt;/i&gt;&lt;0.001). Safety analysis showed that 90.7%(39/43) of patients had postoperative distance visual acuity that remained stable or improved, with only 9.3%(4/43) experiencing a decline; for near visual acuity, 51.2% improved by 2 or more lines and only 2.3% declined. At 6 months, the root m","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"62 8","pages":"602-611"},"PeriodicalIF":0.0,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research progress on intraocular lens power calculation in cataract patients with keratoconus].","authors":"Y X Zhu, X H Xie, J Q Zhang, L X Luo","doi":"10.3760/cma.j.cn112142-20250928-00395","DOIUrl":"https://doi.org/10.3760/cma.j.cn112142-20250928-00395","url":null,"abstract":"<p><p>Keratoconus (KCN) is a progressive corneal ectasia disorder characterized by thinning and steepening of the cornea. Intraocular lens (IOL) power calculation in cataract patients with KCN often leads to a significant hyperopic prediction error. This is attributable to several factors, including inaccurate keratometry, an altered anterior-to-posterior corneal curvature ratio and erroneous prediction of the effective lens position (ELP). Recent studies have shown that KCN-specific formulas such as the Barrett True-K (BTK) formula and the Kane KCN formula can significantly improve refractive prediction accuracy. This review examines the influence of KCN on IOL power calculations, evaluates the performance of previous formulas in cataract patients with KCN, discusses formula selection strategies based on KCN severity, and systematically summarizes the latest research progress in IOL power calculation, astigmatism correction and IOL power calculation after collagen cross-linking (CXL) for these patients.</p>","PeriodicalId":39688,"journal":{"name":"中华眼科杂志","volume":"62 8","pages":"651-656"},"PeriodicalIF":0.0,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}